Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control (DRIVE)
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Direct Observed Therapy
Sponsored by

About this trial
This is an interventional prevention trial for Hypertension focused on measuring Hypertension, Adherence, Direct Observed Therapy (DOT), RCT
Eligibility Criteria
Inclusion Criteria:
- 18 years and above
- Residing in Oslo/Akershus
- Ambulatory Systolic Daytime Blood Pressure ≥ 135 mmHg
- ≥ 2 antihypertensive medications
- Be able to read and write Norwegian
Exclusion Criteria:
- Critical illness, ongoing treatment
- Known atrial fibrillation
- Known heart valve stenosis
- Myocardial infarction, angina pectoris or stroke the past 6 months
- Known severe renal impairment (eGFR < 30 ml/min/1.73 m2)
- History of DOT prior to ABPM
- Participation in other interventional study
Sites / Locations
- Oslo University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Direct Observed Therapy
Control
Arm Description
Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.
Standard care
Outcomes
Primary Outcome Measures
Change in 24-hour ambulatory mean systolic daytime blood pressure
Secondary Outcome Measures
Change in mean office systolic blood pressure
Full Information
NCT ID
NCT02362893
First Posted
February 9, 2015
Last Updated
August 27, 2019
Sponsor
Oslo University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02362893
Brief Title
Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control
Acronym
DRIVE
Official Title
Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control
Study Type
Interventional
2. Study Status
Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
April 2015 (undefined)
Primary Completion Date
July 2018 (Actual)
Study Completion Date
December 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to access the change in mean daytime systolic blood pressure in participants with essential hypertension not adequately controlled (defined as mean systolic daytime ambulatory blood pressure ≥ 135 mmHg) and randomly assigned to either an intervention group with one-time only Direct Observed Therapy (DOT) immediately followed by ABPM or a control group with standard ABPM.
Detailed Description
More than 1 billion people world wide suffer from hypertension (HT), leaving it the world´s top rank risk factor and contributor to global disease burden. Cardiac disease, stroke, kidney disease and dementia are diseases related to HT with high economic burden on societies and each year 9.4 million people die as a direct consequence of HT.
Estimated < 50 % of hypertensive patients adhere to preventive hypertensive medication after 1 year of treatment.
Poor adherence to antihypertensive treatment have by many been explained partly by the silent nature of hypertension, the risk of side effects from antihypertensive medication, treatment expenditures and the patient health perspectives.
In a randomized controlled trial design we plan to enrol 20 subjects, the limited number explained by the study being part of the initial planning of a larger scale trial organized by the research group, to invistigate the change in ambulatory bloodpressure with or with out Direct Observed Theraphy prior to meassurement, as a one-time-only medication adherence check.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Adherence, Direct Observed Therapy (DOT), RCT
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Direct Observed Therapy
Arm Type
Experimental
Arm Description
Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Standard care
Intervention Type
Other
Intervention Name(s)
Direct Observed Therapy
Other Intervention Name(s)
DOT
Intervention Description
Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
Primary Outcome Measure Information:
Title
Change in 24-hour ambulatory mean systolic daytime blood pressure
Time Frame
Measurement at follow-up visit 3 weeks ± 7 days relative to baseline.
Secondary Outcome Measure Information:
Title
Change in mean office systolic blood pressure
Time Frame
Measurement at follow-up visit 3 weeks ± 7 days relative to baseline.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years and above
Residing in Oslo/Akershus
Ambulatory Systolic Daytime Blood Pressure ≥ 135 mmHg
≥ 2 antihypertensive medications
Be able to read and write Norwegian
Exclusion Criteria:
Critical illness, ongoing treatment
Known atrial fibrillation
Known heart valve stenosis
Myocardial infarction, angina pectoris or stroke the past 6 months
Known severe renal impairment (eGFR < 30 ml/min/1.73 m2)
History of DOT prior to ABPM
Participation in other interventional study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aud Høieggen, MD PhD
Organizational Affiliation
Oslo University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oslo University Hospital
City
Oslo
ZIP/Postal Code
0407
Country
Norway
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
23836798
Citation
Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjonnaess E, Hjornholm U, Kjaer VN, Rostrup M, Kjeldsen SE, Os I, Stenehjem AE, Hoieggen A. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013 Sep;62(3):526-32. doi: 10.1161/HYPERTENSIONAHA.113.01452. Epub 2013 Jul 8.
Results Reference
background
PubMed Identifier
24591332
Citation
Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjonnaess E, Hjornholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Hoieggen A. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014 May;63(5):991-9. doi: 10.1161/HYPERTENSIONAHA.114.03246. Epub 2014 Mar 3.
Results Reference
background
Learn more about this trial
Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control
We'll reach out to this number within 24 hrs